[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100405426":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":33,"responsibleParty":77,"collaborators":20,"id":79,"slug":20,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":20,"eligibilityCriteria":84,"healthyVolunteers":80,"sex":85,"minAge":20,"maxAge":86,"enrollmentInfo":87,"targetDuration":20,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":49,"whyStopped":20,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Centre de recherche du Centre hospitalier universitaire de Sherbrooke","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Single arm with 68Ga-DOTATATE","EXPERIMENTAL","all participants will undergo a PET scan with 68Ga-DOTATATE",[13],"Biological: Radiopharmaceutical 68Ga-DOTATATE",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","Radiopharmaceutical 68Ga-DOTATATE","Injection of 68Ga-DOTATATE followed by PET\u002FCT acquisition",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Etienne Rousseau, MD, FRCPC","CIUSSSE-CHUS","PRINCIPAL_INVESTIGATOR",[27],{"name":28,"role":29,"phone":30,"phoneExt":31,"email":32},"Amelie Tetu, MSc","CONTACT","819-346-1110","15571","amelie.tetu.ciussse-chus@ssss.gouv.qc.ca",[34,47,62],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":20},"McGill University Health Center - Children's hospital","WITHDRAWN","Montreal","Quebec","H4A 3J1","Canada",{"type":42,"coordinates":43},"Point",[44,45],-73.58781,45.50884,{"lat":45,"lon":44},{"facility":48,"status":49,"city":37,"state":38,"zip":50,"country":40,"cosmosGeoPoint":51,"geoPoint":53,"contacts":54},"CHU Ste-Justine","RECRUITING","J1H 5N4",{"type":42,"coordinates":52},[44,45],{"lat":45,"lon":44},[55,60],{"name":56,"role":29,"phone":57,"phoneExt":58,"email":59},"Marie Galopin","514-345-4931","6326","marie.galopin.hsj@ssss.gouv.qc.ca",{"name":61,"role":25,"phone":20,"phoneExt":20,"email":20},"Sophie Turpin, MD",{"facility":63,"status":49,"city":64,"state":38,"zip":50,"country":40,"cosmosGeoPoint":65,"geoPoint":69,"contacts":70},"CIUSSS de l'Estrie-CHUS Hospital","Sherbrooke",{"type":42,"coordinates":66},[67,68],-71.89908,45.40008,{"lat":68,"lon":67},[71,75,76],{"name":72,"role":29,"phone":30,"phoneExt":73,"email":74},"Etienne Croteau, PhD","11894","etienne.croteau.ciussse-chus@ssss.gouv.qc.ca",{"name":28,"role":29,"phone":30,"phoneExt":31,"email":32},{"name":23,"role":25,"phone":20,"phoneExt":20,"email":20},{"type":78,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100405426",false,"NCT04559217","68Ga-DOTATATE Neuroblastoma Imaging Pilot","Pilot Study of 68Ga-DOTATATE PET\u002FCT and 123I-MIBG Scintigraphy Imaging of Neuroblastoma","Inclusion Criteria:\n\n* Newly suspected or biopsy-proven neuroblastoma or recurrence of neuroblastoma\n* Planned 123I-MIBG imaging\n* Able and willing to provide signed informed consent in French or English (for the adult candidates or the parent\u002Flegal tutor of the pediatric candidates)\n* Aged between 1 day and 21 years old (inclusively).\n\nExclusion Criteria:\n\n* History of another cancer in the past 5 years other than non-melanomatous skin cancer.\n* Currently under a randomized control trial with unknown allocation;\n* Currently under treatment;\n* Medical\u002Fsurgical intervention on the tumour between 123I-MIBG and 68Ga-DOTATATE PET\u002FCT scan.\n* Medically unstable or unable to undergo scan.\n* Pregnancy (breastfeeding is not an exclusion criterion but needs to be stopped for at least 12 hours after 68Ga-DOTATATE injection).\n* Prior allergic reaction to somatostatin analogues","ALL","21 Years",{"count":88,"type":89},20,"ESTIMATED","INTERVENTIONAL",[92],"PHASE2","Neuroblastoma is the most frequent extracranial childhood tumor, with an annual incidence of approximately 10.2 per million children. Staging of the disease can be done by different imaging strategies (CT, MRI, scintigraphy and PET\u002FCT). Discrepancies may be observed among these different strategies resulting in different treatment strategies. The goal of this study is to assess the feasibility and safety of 68Ga-DOTATATE and to compare it to 123I-MIBG when investigating neuroblastoma.",[95],"Neuroblastoma",[97,98,99,100],"imaging","68Ga-Dotatate","68Ga-Octreotate","positron emission tomography (PET)","2026-05-26",{"date":103,"type":104},"2026-05-27","ACTUAL",{"date":106,"type":104},"2021-12-06",{"date":108,"type":89},"2028-09-30",{"name":5,"class":6},3]